Syncona leads Freeline's £88M series B

Freeline Therapeutics Ltd. (London, U.K.) raised £88.4 million ($116.9 million) on June 19 in a series B round which included £85 million from lead investor Syncona Ltd. (LSE:SYNC). Fellow founding investor UCL Technology Fund also participated, providing £3.4 million.

Freeline has a gene therapy platform to develop adeno-associated virus (AAV) vectors that transduce liver cells and deliver a functional gene copy. Its FLT180a, a replication-incompetent AAV vector containing DNA encoding Factor IX, is in a Phase I/II trial to treat hemophilia B. It expects data within the next year...